Vis enkel innførsel

dc.contributor.authorEllingsen, Trygve
dc.contributor.authorLappegård, Jostein
dc.contributor.authorUeland, Thor
dc.contributor.authorAukrust, Pål
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2019-01-07T08:49:32Z
dc.date.available2019-01-07T08:49:32Z
dc.date.issued2018
dc.description.abstractRed cell distribution width (RDW) is associated with venous thromboembolism (VTE), but the underlying mechanism(s) is unclear. Iron deficiency is associated with high RDW, and studies suggest an association between iron deficiency and VTE. To assess whether iron deficiency is a risk factor for VTE that explains the association between RDW and VTE, we conducted a nested case-control study of 390 patients with VTE and 802 age- and sex-matched controls selected from the population-based cohort of the Tromsø Study. Physical measurements and blood samples were collected from 1994 to 1995. Logistic regression models were used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE by RDW, hepcidin, and ferritin light chain (FtL). RDW was inversely associated with hepcidin, FtL, and hemoglobin. The risk of VTE increased linearly across categories of higher plasma hepcidin levels. Participants with hepcidin in the highest quartile had an OR for VTE of 1.32 (95% CI, 1.00-2.42), and those in the >90% percentile had an OR for VTE of 1.66 (95% CI, 1.14-2.42) compared with the reference group (quartiles 2 and 3). The risk estimates remained similar after adjustment for C-reactive protein. The risk of VTE increased by categories of higher RDW and was strengthened after inclusion of hepcidin and FtL in the multivariable model. Our findings reject the hypothesis that iron deficiency explains the association between RDW and VTE and suggest, in contrast, that high body iron levels might increase the risk of VTE.en_US
dc.description.sponsorshipStiftelsen Kristian Gerhard Jebsenen_US
dc.descriptionSource at <a href=https://doi.org/10.1182/bloodadvances.2018018465> https://doi.org/10.1182/bloodadvances.2018018465</a>.en_US
dc.identifier.citationEllingsen, T.S., Lappegård, J., Ueland, T., Aukrust, P., Brækkan, S.K. & Hansen, J.B. (2018). Plasma hepcidin is associated with future risk of venous thromboembolism. <i>Blood Advances</i>, 2(11), 1191-1197. https://doi.org/10.1182/bloodadvances.2018018465en_US
dc.identifier.cristinIDFRIDAID 1589313
dc.identifier.doi10.1182/bloodadvances.2018018465
dc.identifier.issn2473-9529
dc.identifier.issn2473-9537
dc.identifier.urihttps://hdl.handle.net/10037/14383
dc.language.isoengen_US
dc.publisherAmerican Society of Hematologyen_US
dc.relation.journalBlood Advances
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Hematology: 775en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Hematologi: 775en_US
dc.titlePlasma hepcidin is associated with future risk of venous thromboembolismen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel